DexCom reported mixed Q2 results with an earnings beat, but revenue missed expectations. The company lowered its full-year revenue guidance. DexCom's steep valuation is only justifiable with sustained ...
DexCom (NasdaqGS:DXCM) is seeing higher adoption of its continuous glucose monitoring systems among patients using GLP-1 drugs, as physicians pair both therapies for diabetes care. The company is ...
DexCom's growth rate has been declining over multiple periods. The company expects as little as 1% organic growth for the current quarter. Investors may see this as proof that GLP-1 drugs are ...
We recently published 10 Stocks Bleeding Early. DexCom, Inc. (NASDAQ:DXCM) is one of the worst-performing stocks on Monday. DexCom fell for a fifth straight day on Monday, shedding 3.82 percent to ...
Shares of medical device company DexCom (NASDAQ:DXCM) jumped 7.3% in the morning session after it reported ...
Zacks Investment Research on MSN
DexCom (DXCM) Q4 earnings and revenues top estimates
DexCom (DXCM) came out with quarterly earnings of $0.68 per share, beating the Zacks Consensus Estimate of $0.65 per share. This compares to earnings of $0.45 per share a year ago. These figures are ...
DexCom, Inc. is a medical device company specializing in continuous glucose monitors for insulin monitoring. Following a 33% drop in stock price after Q2 earnings, DexCom's lowered guidance still ...
Medical device company DexCom (NASDAQ:DXCM) announced better-than-expected revenue in Q4 CY2025, with sales up 13.1% year on year to $1.26 billion. The company expects the full year’s revenue to be ...
SAN DIEGO--(BUSINESS WIRE)--This World Diabetes Day, DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing technology, is encouraging people with diabetes globally to take the first ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results